Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the closing of its previously announced upsized underwritten public offering of 7,697,812 shares of its common stock at a public offering price of $32.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,004,062 shares of common stock in the offering. The gross proceeds to Amylyx from the offering were $246.3 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Goldman Sachs & Co. LLC, BofA Securities, SVB Securities, and Evercore ISI acted as joint book-running managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering.

Registration statements on Form S-1 relating to these securities became effective on October 6, 2022. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: Goldman Sachs & Co. LLC, at Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526 or by e-mail at [email protected]; BofA Securities, Inc., Attention: Prospectus Department, 200 North College Street, 3rd floor, Charlotte NC 28255-0001 or by email at [email protected]; SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525, ext. 6105, or by email at [email protected]; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at 1-888-474-0200, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221011005927/en/

Media

Becky Gohsler
Finn Partners
(646) 307-6307
[email protected]

Investors

Lindsey Allen
Amylyx Pharmaceuticals, Inc.
(857) 320-6244
[email protected]

Source: Amylyx Pharmaceuticals, Inc.

You May Also Be Interested In

• Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $3 at Baird on latest AMX0035 data
• Veefin partners with Computech Limited to Digitally Transform BFSI Industry through Supply Chain Finance & Digital Lending in Africa
• CancerVax Announces Promising New Drug to Treat a Deadly Children’s Cancer